References: Greg T. Hermanson, Bioconjugate Techniques, 3rd Edition, Elsevier, Waltham, MA 02451, 2013, ISBN 978-0-12-382239-0; See Chapter 18, Discrete PEG Reagents, pp. 787-821, for a full overview of the dPEG® products.
Product number 10342, amino-dPEG®12-ODMT, was designed for nucleic acid modification in applications where PEGylation improves the therapeutic or diagnostic profile.
Nucleic acid aptamers are single-stranded DNA or RNA oligonucleotide sequences of approximately 20 – 100 nucleotides that bind specific target molecules with high affinity1,2. Nucleic acid aptamers have low immunogenicity and can be synthesized chemically in large quantities (mg up to kg) at very high purity and much lower cost than antibodies or other biologically derived therapeutic molecules.1,3. Because of their high affinity for targeted molecules, nucleic acid aptamers have fewer off-target effects than antibodies1,2. These aptamers, however, are quickly excreted from the body due to their small size or are rapidly degraded by nucleases3,4. PEGylation protects nucleic acid aptamers from enzymatic degradation in vivo and can extend in vivo serum half-life of these aptamers by increasing the hydrodynamic volume1-4.
Following oligonucleotide synthesis, amino-dPEG®12-ODMT can be conjugated to phosphate groups on either end of the chain using water-soluble 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) chemistry. The 4,4′-dimethoxytrityl group can then be removed using a weak acid, such as dilute dichloroacetic acid, leaving the dPEG® linker terminated with a hydroxy group. Studies have shown that 3′ end capping (including PEGylation) helps the oligonucleotide chain resist nuclease degradation, while 5′ end PEGylation reduces renal clearance of the aptamer3.
If you need bulk product in a larger package size than our standard sizes, please contact us for a quote. Our commercial capabilities permit us to manufacture this product at any scale that you need.
Röthlisberger, P.; Gasse, C.; Hollenstein, M. Nucleic Acid Aptamers: Emerging Applications in Medical Imaging, Nanotechnology, Neurosciences, and Drug Delivery. International Journal of Molecular Sciences2017, 18(11), 2430. https://doi.org/10.3390/ijms18112430.
Ni, S.; Yao, H.; Wang, L.; Lu, J.; Jiang, F.; Lu, A.; Zhang, G. Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes. International Journal of Molecular Sciences2017, 18(8), 1683. https://doi.org/10.3390/ijms18081683.
Becker, R.; Povsic, T.; Cohen, M. G.; Rusconi, C.; Sullenger, B. Nucleic Acid Aptamers as Antithrombotic Agents: Opportunities in Extracellular Therapeutics. Thromb Haemost2010, 103 (3), 586–595. https://doi.org/10.1160/TH09-10-0716.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.